$Summit Therapeutics(SMMT.US)$ i think this stock may be ready to crash. still no income, the whole company betting on the approval of ivonescinab, riiisky
2
举报
JESSE JAMES8832 :
i see there whole pipeline consists of different variantes of iovnescinab
$Summit Therapeutics(SMMT.US)$Ankur Dhingra, Chief Financial Officer, on March 26, 2024, executed a purchase for 100,000 shares in Summit Therapeutics (SMMT) for $375,000. Following the Form 4 filing with the SEC, Dhingra has control over a total of 354,958 shares of the company, with 354,958 shares controlled indirectly.
SlowndEasyTradesTrytosaveabit楼主:
It’s not real swing trade sell at resistance longer hold type small bet only I don’t like swing trade below 5$ valuation anyway
Trytosaveabit楼主SlowndEasyTrades:
I consider anything longer than a day, a swing! Whether I’m looking for bottom to buy and hold for data/PR/deal! And could hold for 6/8+ weeks! Others swings are severely OS ATL/Near ATL/52WKL with a chart that’s saying reversal coming!
$Summit Therapeutics(SMMT.US)$Summit Therapeutics Announced Data For Ivonescimab In Advanced Non-small Cell Lung Cancer, That Is Being Presented At The 2024 European Lung Cancer Congress Benzinga· 3 mins ago Ivonescimab alone or combined with chemotherapy led to intracranial responses among 34% of patients with brain metastases at baseline – 23% achieved a complete response All patients who did not achieve an intracranial response demonstrated stable disease or non-progression by RANO cri...
$Summit Therapeutics(SMMT.US)$Officer Dhingra Ankur purchased 20,400 shares of Common Stocks on Dec 13, 2023 at an average price of $2.17 for a total value of $44,254. Officer Zanganeh Mahkam purchased 5,000 shares of Common Stocks on Dec 12, 2023 at an average price of $2.07 for a total value of $10,350.
Summit Therapeutics股票讨论区
i think this stock may be ready to crash. still no income, the whole company betting on the approval of ivonescinab, riiisky
加载中...
加载中...
Benzinga· 3 mins ago
Ivonescimab alone or combined with chemotherapy led to intracranial responses among 34% of patients with brain metastases at baseline – 23% achieved a complete response
All patients who did not achieve an intracranial response demonstrated stable disease or non-progression by RANO cri...
Officer Zanganeh Mahkam purchased 5,000 shares of Common Stocks on Dec 12, 2023 at an average price of $2.07 for a total value of $10,350.
$阿莎娜(ASAN.US)$ alerted 17
暂无评论